COVID-19 Infection in Patients Receiving Anti-CD20 Therapy
NCT04884477 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 342
Last updated 2023-03-01
Summary
This study is being conducted to determine if patients with compromised B-cell function due to anti-CD20 therapy and newly diagnosed COVID-19 infection benefit from convalescent plasma.
Conditions
- COVID-19
- Immunosuppressed Host
- Convalescent Plasma
- Anti-CD20 Therapy
Interventions
- BIOLOGICAL
-
Convalescent Plasma
Convalescent Plasma
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Mary Kasten, MD · Mayo Clinic
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-06-01
- Primary Completion
- 2023-01-15
- Completion
- 2023-01-15
Countries
- United States
Study Locations
More Related Trials
-
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
NCT04474340 ·Status: UNKNOWN ·Phase: PHASE1
-
Convalescent Plasma for Patients With COVID-19
NCT04385199 ·Status: COMPLETED ·Phase: PHASE2
-
Collection of Anti-SARS-CoV-2 Immune Plasma
NCT04344977 ·Status: COMPLETED
-
Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection
NCT04408209 ·Status: COMPLETED ·Phase: NA
-
Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure
NCT04428021 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma Therapy in Severe COVID-19 Infection
NCT04403477 ·Status: UNKNOWN ·Phase: PHASE2
-
Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)
NCT04390178 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
NCT04554992 ·Status: COMPLETED ·Phase: PHASE1
-
Convalescent Plasma vs. Standard Plasma for COVID-19
NCT04344535 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19
NCT04433910 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma for Early Treatment of COVID-19
NCT04390503 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19
NCT04438057 ·Status: COMPLETED ·Phase: PHASE2
-
Plasma Therapy of COVID-19 in Severely Ill Patients
NCT04359810 ·Status: COMPLETED ·Phase: PHASE2
-
Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients
NCT04621123 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma Therapy in Patients With COVID-19
NCT04407208 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
NCT04392232 ·Status: COMPLETED ·Phase: PHASE2
-
COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
NCT04397757 ·Status: COMPLETED ·Phase: PHASE1
-
Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients
NCT04420988 ·Status: NO_LONGER_AVAILABLE
-
Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19
NCT04467151 ·Status: WITHDRAWN ·Phase: PHASE2
-
COVID-19 Convalescent Plasma for Mechanically Ventilated Population
NCT04388527 ·Status: COMPLETED ·Phase: PHASE1
-
CoVID-19 Plasma in Treatment of COVID-19 Patients
NCT04355897 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Convalescent Plasma to Limit Coronavirus Associated Complications
NCT04325672 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)
NCT04547127 ·Status: COMPLETED ·Phase: PHASE2
-
Convalescent Plasma for Treatment of COVID-19
NCT04649879 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Convalescent Plasma in the Treatment of Covid-19
NCT04730401 ·Status: UNKNOWN ·Phase: PHASE2